Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 15 for:    PKM

The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01968928
Recruitment Status : Unknown
Verified October 2013 by National Taiwan University Hospital.
Recruitment status was:  Not yet recruiting
First Posted : October 24, 2013
Last Update Posted : October 28, 2013
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
Bladder urothelial carcinoma (UC) is a common malignancy and the incidence is increasing by years in Taiwan. Chemoresistance was inevitable in treatment of metastatic disease and lead to the ominous outcomes. To develop novel therapeutic strategies to overcome chemoresistance is imperative. Cancer cells uptake glucose at higher rates than normal tissue but use most of glucose for glycolysis even under normoxia condition, which is known as the Warburg effect. Pyruvate kinase (PK) catalyzes the last step in the process of glycolysis, and one of it isoform--PKM2 has been reported to be associated with tumor progression and some specific tissues and promotes the Warburg effect in cancer cells.

Condition or disease
Bladder Urothelial Carcinoma

Detailed Description:

Regulation of PKM2 can be a novel target of cancer therapy. Meanwhile, PKM2 may play a critical role in the development of drug resistance and can be a promising target to overcome drug resistance.

In this study, our specific aims are as follows:

  1. To prove the differentia expression levels of PKM2 in UC cells and drug-resistant UC cells, as well as in human UC tissues and drug-resistant UC tissues.
  2. To examine the effect of PKM2 regulations(PKM2 siRNA and shikonin)on invasiveness and metastatic ability of UC cells and clarify the role of PKM2 in human UC cells.
  3. To investigate the combinatory effect of PKM2 regulations(PKM2 siRNA and shikonin)and currently used chemotherapeutic agents (cisplatin,gemcitabine ,doxorubicin). Do PKM2 regulations enhance the cytotoxic effect of chemotherapy and overcome the chemoresistance?
  4. To further prove the in vitro findings in the nude mice xenograft model。

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 25 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Day
Official Title: The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
Study Start Date : January 2014
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2016


Group/Cohort
drug-resistant
specimens com from drug-resistant bladder urothelial carcinoma patients.
normal
specimens come from normal bladder urothelial carcinoma patients.
non-tumoral
specimens come from non-tumoral patients.



Primary Outcome Measures :
  1. The IHC score [ Time Frame: at the time of surgery ]
    the IHC scores are acquired by IHC staining and the comparisons between each specimen are determined by IHC scores.


Biospecimen Retention:   None Retained
Tissue samples of tumors as well as normal-appearing mucosa collected in the tissue bank are to be used to examine the cellular and molecular events involved. Comparisons will be made to differentiate cellular changes between tumors and the normal counterparts.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with age between 20-80 years old and had taken Radical Cystectomy or nephrectomy between 2008-2012 were chosen as study population.
Criteria

Inclusion Criteria:

  • patients with age between 20-80 years old and had taken Radical Cystectomy or nephrectomy between 2008-2012

Exclusion Criteria:

  • patients with age not located in the interval of 20-80 years old.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01968928


Contacts
Layout table for location contacts
Contact: Kuo-How Huang, M.D., Ph. D 886-2-23123456 ext 65952 khhuang123@ntu.edu.tw
Contact: Chin-Ling Huang 886-2-23123456 ext 65233

Locations
Layout table for location information
Taiwan
Department of Urology, National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan, 10002
Contact: Kuo-How Huang, M.D.,Ph.D.    886-2-23123456 ext 65952    khhuang123@ntu.edu.tw   
Principal Investigator: Kuo-How Huang, M.D.,Ph.D.         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Kuo-How Huang, M.D., Ph.D. Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

Additional Information:

Publications:
Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01968928     History of Changes
Other Study ID Numbers: 201308044RIN
First Posted: October 24, 2013    Key Record Dates
Last Update Posted: October 28, 2013
Last Verified: October 2013

Keywords provided by National Taiwan University Hospital:
Bladder urothelial carcinoma (UC)
pyruvate kinase
drug resistance
shikonin

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms